ReviewOrphanet journal of rare diseases2022

Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?

Maarten J Postma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.